Eli Lilly & Free Cash Flow (FCF) History (LLY)

Eli Lilly & reported $8.97B in free cash flow for fiscal 2025, an increase of 138.62% from the previous fiscal year, with a free cash flow margin of 13.77%.

View full Eli Lilly & company overview

Eli Lilly & free cash flow by year

Eli Lilly & annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31$8.97B$5.21B+138.62%+13.77%
20242024-12-31$3.76B$2.97B+374.75%+8.35%
20232023-12-31$792.0M−$4.94B−86.18%+2.32%
20222022-12-31$5.73B−$324.7M−5.36%+20.08%
20212021-12-31$6.06B$944.4M+18.48%+21.39%
20202020-12-31$5.11B$1.31B+34.42%+20.83%
20192019-12-31$3.80B−$511.2M−11.85%+17.04%
20182018-12-31$4.31B−$224.9M−4.96%+20.07%
20172017-12-31$4.54B$724.8M+19.00%+22.72%
20162016-12-31$3.81B$1.92B+100.91%+17.97%
20152015-12-31$1.90B−$1.40B−42.40%+9.51%
20142014-12-31$3.30B−$1.43B−30.22%+16.80%
20132013-12-31$4.72B$323.5M+7.35%+20.43%
20122012-12-31$4.40B−$2.16B−32.96%+19.46%
20112011-12-31$6.56B$400.0M+6.49%+27.02%
20102010-12-31$6.16B$2.59B+72.59%+26.71%
20092009-12-31$3.57B−$2.78B−43.76%+16.35%
20082008-12-31$6.35B$2.28B+55.90%+31.16%
20072007-12-31$4.07B+21.85%

Eli Lilly & free cash flow growth trends

Over the last five reported fiscal years, free cash flow grew from $5.11B to $8.97B, a compound annual growth rate of 11.91%. Eli Lilly &'s latest reported quarter, Q2 2026, generated $7.76B in free cash flow, an increase of 458.06% year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Eli Lilly & filings at SEC.gov ↗